This inventor holds 1 USPTO granted patent and 5 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Italfarmaco Spa. Active years: 2016.
Company Filing History:
Years Active: 2016
Title: The Innovative Contributions of Alessandro Rambaldi
Introduction
Alessandro Rambaldi is a notable inventor based in Bergamo, Italy. He has made significant contributions to the field of medicine, particularly in the treatment of myeloproliferative syndromes. His innovative approach has led to the development of a unique method that addresses a critical health issue.
Latest Patents
Rambaldi holds a patent titled "Use of histone deacetylase inhibitors for the care of Philadelphia-negative myeloproliferative syndromes." This patent outlines a method for treating patients suffering from Philadelphia-negative myeloproliferative syndromes. The method involves administering diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride, or other pharmaceutically acceptable salts and/or solvates, in a daily dosage ranging from 10 to 150 mg per patient. This innovative treatment has the potential to improve the quality of life for many patients.
Career Highlights
Rambaldi is associated with Italfarmaco Spa, a company known for its commitment to pharmaceutical advancements. His work at Italfarmaco has allowed him to focus on developing effective treatments for complex medical conditions. His dedication to research and innovation has positioned him as a key figure in the pharmaceutical industry.
Collaborations
Throughout his career, Rambaldi has collaborated with esteemed colleagues such as Tiziano Oldoni and Paolo Mascagni. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, ultimately leading to groundbreaking advancements in medical treatments.
Conclusion
Alessandro Rambaldi's contributions to the field of medicine through his innovative patent and collaborative efforts highlight his commitment to improving patient care. His work continues to inspire advancements in the treatment of myeloproliferative syndromes.